Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

被引：0
|
作者：
B. Schultheis
G. Kummer
M. Zeth
E. Brendel
C. Xia
M. Kornacker
D. Strumberg
机构：
[1] University of Bochum (Marienhospital Herne),Department of Haematology and Medical Oncology
[2] Bayer HealthCare Pharmaceuticals,undefined
[3] Bayer HealthCare Pharmaceuticals,undefined
[4] Bayer HealthCare Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Phase I; Sorafenib; Gemcitabine; Cisplatin; Multiple kinase inhibitor; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：333 / 339
页数：6
相关论文
共 50 条
  • [41] Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies
    Haigentz, M
    Kim, M
    Sorich, J
    Lee, J
    Hochster, H
    Macapinlac, M
    Mirchandani, D
    Sewak, S
    Pavlick, A
    Volm, M
    Hamilton, A
    Muggia, FM
    ANTI-CANCER DRUGS, 2003, 14 (04) : 321 - 326
  • [42] Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Aravantinos, G
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kostopoulou, V
    Mylonakis, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 493 - 497
  • [43] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
    Meany, Holly Jane
    Dome, Jeffrey
    Hinds, Pamela S.
    Bagatell, Rochelle
    Shusterman, Suzanne
    Widemann, Brigitte C.
    Stern, Emily
    London, Wendy B.
    Kim, AeRang
    Fox, Elizabeth
    Rodriguez-Galindo, Carlos
    Minturn, Jane E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
    Italiano, A.
    Infante, J. R.
    Shapiro, G., I
    Moore, K. N.
    LoRusso, P. M.
    Hamilton, E.
    Cousin, S.
    Toulmonde, M.
    Postel-Vinay, S.
    Tolaney, S.
    Blackwood, E. M.
    Mahrus, S.
    Peale, F., V
    Lu, X.
    Moein, A.
    Epler, J.
    DuPree, K.
    Tagen, M.
    Murray, E. R.
    Schutzman, J. L.
    Lauchle, J. O.
    Hollebecque, A.
    Soria, J-C
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1304 - 1311
  • [45] Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors
    Infante, Jeffrey R.
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Bauer, Todd
    Blackwood, Beth
    Evangelista, Marie
    Mahrus, Sami
    Peale, Frank
    Lu, Xuyang
    Sahasranaman, Srikumar
    Zhu, Rui
    Chen, Yuan
    Ding, Xiao
    Murray, Elaine
    Schutzman, Jennifer
    Lauchle, Jennifer
    Soria, Jean-Charles
    LoRusso, Patricia
    CANCER RESEARCH, 2015, 75
  • [46] Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
    Kao, Chien-Chang
    Ho, Ching-Liang
    Yang, Ming-Hsin
    Tsai, Yi-Ta
    Liu, Shu-Yu
    Chang, Ping-Ying
    Wu, Yi-Ying
    Chen, Jia-Hong
    Yehn, Ren-Hua
    Dai, Ming-Shen
    Chen, Yeu-Chin
    Sun, Guang-Huan
    Cha, Tai-Lung
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [47] A Phase Ib study of ruxolitinib plus gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
    Bauer, Todd M.
    Patel, Manish R.
    Forero-Torres, Andres
    George, Thomas J., Jr.
    Assad, Albert
    Du, Yining
    Hurwitz, Herbert
    ONCOTARGETS AND THERAPY, 2018, 11 : 2399 - 2407
  • [48] Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
    Infante, Jeffrey R.
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Bauer, Todd M.
    Blackwood, Elizabeth M.
    Evangelista, Marie
    Mahrus, Sami
    Peale, Franklin V.
    Lu, Xuyang
    Sahasranaman, Srikumar
    Zhu, Rui
    Chen, Yuan
    Ding, Xiao
    Murray, Elaine R.
    Schutzman, Jennifer L.
    Lauchle, Jennifer O.
    Soria, Jean-Charles
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2423 - 2432
  • [49] Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
    Kauh, J. S.
    Harvey, R. D.
    Lawson, D. H.
    Owonikoko, T. K.
    Tighiouart, M.
    Ramalingam, S. S.
    Shin, D. M.
    Lewis, C. M.
    El-Rayes, B. F.
    Khuri, F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Phase I study of sorafenib, pemetrexed, and cisplatin for the treatment of advanced solid tumors
    Fujioka, N.
    Dudek, A.
    Kirstein, M. N.
    Kumar, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345